Articles published by Neuropathix, Inc.


Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
April 13, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX

Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
April 06, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX

Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX

Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
January 18, 2022
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX

Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
November 17, 2021
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Tickers
NPTX


From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX

Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
August 12, 2021
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Tickers
NPTX

From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.